 Home > Active Ingredient News > Antitumor Therapy > Front Oncol: The effect of chemotherapy on the overall survival of patients with metastatic prostate cancer

Front Oncol: The effect of chemotherapy on the overall survival of patients with metastatic prostate cancer

 Last Update: 2021-12-04
 Source: Internet
 Author: User

Tags

greenhouse effect related global warming

biomarkers cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

A randomized clinical trial (RCT) confirmed that chemotherapy improved the overall survival of patients with metastatic prostate cancer
.

However, there is still a lack of large-scale epidemiological data to verify this effect in the real world

A randomized clinical trial (RCT) confirmed that chemotherapy improved the overall survival of patients with metastatic prostate cancer

The study screened patients with newly diagnosed metastatic prostate cancer in the SEER database from 2014 to 2015
.

Kaplan-Meier and Cox regression models analyzed the difference in overall survival between chemotherapy-exposed patients and those without chemotherapy

The study screened patients with newly diagnosed metastatic prostate cancer in the SEER database from 2014 to 2015

Between 2014 and 2015 , 4295 patients with new metastatic prostate cancer were

Clinical features

Clinical featuresClinical features

Before PSM, based on the overall cohort, 905 patients received chemotherapy and 3390 patients without chemotherapy
.

The 18-month and 30-month overall survival rates of chemotherapy and non-chemotherapy patients were 76.

Before PSM, based on the overall cohort, 905 patients received chemotherapy and 3390 patients without chemotherapy

OS comparison before PSM

After PSM, the cohort included 879 patients receiving chemotherapy and 1611 patients without chemotherapy
.

The clinicopathological characteristics are balanced

After PSM, the cohort included 879 patients receiving chemotherapy and 1611 patients without chemotherapy

OS comparison after PSM

Multivariate analysis of related factors

In summary, this real-world data study shows that chemotherapy can improve the overall survival of patients with metastatic prostate cancer
.

However, the magnitude of the overall survival benefit cannot be compared to the phase III trial

In summary, this real-world data study shows that chemotherapy can improve the overall survival of patients with metastatic prostate cancer

Original source:

Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, Shariat SF, Tilki D, Kluth LA, Mandel P, Chun FKH and Karakiewicz PI (2021) Effect of Chemotherapy on Overall Survival in Contemporary MetastaticProstate Cancer Patients.
Front.
Oncol.
11:778858.
doi: 10.
3389/fonc.
2021.
778858

Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, Shariat SF, Tilki D, Kluth LA, Mandel P, Chun FKH .
.
and Karakiewicz PI (2021) Effect of Chemotherapy on Overall Survival in Contemporary MetastaticProstate Cancer Patients Front Oncol 11:.
778858 doi:.
10.
3389 / fonc.
2021.
778858 in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.